BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Axim Biotechnologies, Inc. AXIM
13 fiscal years on record · USD · FY2023 reported · SEC filings only
Growth
USD 39,518.00
Revenue, FY2023 · full 13-year series below
Revenue $M
Net income $M
FY2023 · Revenue 0.0 · Net income -8.1
Compound annual growth
Revenue compounded at −27.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−20395 cents
lost on every revenue dollar
Operating margin
Net margin
FY2023 · Operating -6961.0% · Net -20395.0%
ROE
FY2012 · ROE -541.2%
The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | · | · | · | −0.0 | −0.0 | −0.0 | · | · | · |
| EPS, diluted $ | −0.04 | −0.04 | 0.12 | −0.06 | −0.10 | −0.12 | −0.08 | −0.17 | −0.27 | −0.02 | 0.00 | · | 0.00 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | · | · | · | · | · | · | · | · | · | · | · | −541.2 | −27.4 |
| Shares out B | 0.25 | 0.19 | 0.14 | 0.13 | 0.06 | 0.06 | 0.05 | 0.05 | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 52 reconciliationsAUDITED
Reconciled in 13 of 19 fiscal years. 43 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inNevada
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011